
Treat SELLAS Life Sciences (SLS) as a high-risk watchlist idea, not a confirmed buy: its Phase 3 survival result for GPS is promising, but key trial details and the FDA’s approval path remain uncertain. Wait for the survival curves, analysis population, and final statistical threshold before making an investment decision; the discussion provides no validated price target or specific timeframe. Avoid treating CAPR, SAVA, or CCXI as actionable trades based on these comparisons, which provide no substantiated current thesis or price targets.

By @shkreliplanet